Autism Warning Marks Sharp Break from Standards: Attorneys
A controversial FDA safety communication on acetaminophen and autism — issued immediately after a 9/22 press conference featuring president Donald Trump, HHS secretary Robert F. Kennedy Jr., and FDA commissioner Marty Makary — has drawn sharp concern from legal experts who say the agency appears to be moving away from long-standing procedures for drug labeling and safety warnings.
At the press event, senior officials claimed a causal connection between acetaminophen use during pregnancy and autism, a link not supported by existing scientific consensus. Hours later, FDA announced it had sent a letter to U.S. physicians and initiated a process to add new label warnings to all acetaminophen products.
While FDA’s official notice to clinicians was more measured than the remarks made during the press conference, the agency has not disclosed what language the new label will contain or how the process will unfold, according to attorneys at Mintz writing in a client update. To date, no formal proposal to amend the over-the-counter monograph for acetaminophen has been released, they note.
The attorneys contend that the move marks a departure from FDA’s typical collaborative process with industry. Ordinarily, the agency and product sponsors engage directly to evaluate safety data, negotiate warning language, and jointly revise labeling to reflect emerging risks. That process, which includes scientific vetting and procedural transparency, helps ensure that new warnings are evidence-based and legally defensible, they say.
By contrast, according to the client alert, manufacturers and distributors of branded and generic acetaminophen products were not notified in advance of the agency’s decision to pursue a warning. Many reportedly learned of the change in real time during the administration’s press event. “It appears that this is the first time FDA has sought to impose a labeling warning of this kind on an OTC drug without engaging the sponsor,” the firm writes. “Companies across the FDA-regulated ecosystem should be on alert for similar unilateral actions.”
The implications could extend well beyond acetaminophen, the attorneys warn. If the agency proceeds without sponsor consultation or a formal rulemaking process, drugmakers could challenge such actions as arbitrary or procedurally improper, citing due process or Administrative Procedure Act violations. Additionally, potential downstream effects on product liability and mass tort litigation, since government-imposed warnings — particularly if not supported by robust evidence — can complicate both manufacturer defenses and plaintiff claims, they say.